Scarica l'app Stockscreener
4.26
0.71%
0.03
Dopo l'orario di chiusura:
4.05
-0.21
-4.93%
Precedente Chiudi:
$4.23
Aprire:
$4.15
Volume 24 ore:
170.35K
Relative Volume:
1.20
Capitalizzazione di mercato:
$45.94M
Reddito:
-
Utile/perdita netta:
$-19.09M
Rapporto P/E:
-2.3933
EPS:
-1.78
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
-0.47%
1M Prestazione:
+32.71%
6M Prestazione:
-21.11%
1 anno Prestazione:
-3.62%
Intervallo 1D:
$4.00
$4.41
Intervallo di 1 settimana:
$3.55
$4.41
Portata 52W:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Confronta LTRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.26 | 43.46M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com
Will Lantern Pharma Inc. stock benefit from interest rate changesExplosive portfolio gains - jammulinksnews.com
Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional
What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional
Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com
Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire
What analysts say about Lantern Pharma Inc. stockTremendous gains - jammulinksnews.com
Is Lantern Pharma Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest
Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail
IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire
Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser
Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener
Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com India
Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus
Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com South Africa
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire
What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):